MAM
Lowe snatches Bajaj Discover creative duties from O&M
MUMBAI: It is celebration time at the Lowe stable as yet another Bajaj account lands in Lowe’s Kitty. Bajaj Discover, which was being handled by O&M, has just moved to Lowe. In effect, now Lowe handles 3 of the 4 Bajaj bike brands – CT 100, Avenger and Discover.
Bajaj Auto GM marketing KS Grahapati confirmed the same to Indiantelevision.com, stating that the account moved last week, although he did not divulge any details on the reason for the shift.
Lowe’s senior vice-president Tarun Chauhan confirmed the development as well.
Flashing back to the close of 2004, Bajaj saw it consolidate its bike accounts with Leo Burnett bagging Pulsar, Lowe taking Bajaj CT 100 and Avenger and O&M bagging Bajaj Discover.
O&M in 2004 had roped in Jackie Chan for the launch commercial of Bajaj Discover. The bike, which was launched in the first week of October 2004, was priced at Rs 39,997.
The two wheeler category has primarily three segments – Premium / sport, commuter/economy and the aggregative segment.
While Pulsar straddles the premium segment, CT 100 is in the economy lane. In the aggregative segment, Bajaj earlier had Wind and Calibre, both of which were phased out to be replaced by Discover.
The Discover brand is being re-launched and the campaign will hit the tube in third week of August.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
